Innate Pharma S.A. (NASDAQ:IPHA) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET
Company Participants
Henry Wheeler - Vice President, Investor Relations and Communications
Jonathan Dickinson - Chief Executive Officer
Sonia Quaratino - Chief Medical Officer
Yannis Morel - Chief Operating Officer
Frederic Lombard - Chief Financial Officer
Arvind Sood - Executive Vice President U.S. Operations
Conference Call Participants
Daina Graybosch - Leerink Partners
Rajan Sharma - Goldman Sachs
Arthur He - HCW
Operator
Hello and thank you for standing by. My name is Regina and will be your conference operator today. At this time, I would like to welcome everyone to the Innate Pharma’s Third Quarter 2024 Business Update and Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions]
I would now like to turn the conference over to Henry Wheeler, Vice President, Investor Relations. Please go ahead.
Henry Wheeler
Thank you. Good morning, good afternoon, and welcome everyone. This morning Innate issued a press release for our Q3 2024 business updates and financial results. We look forward to highlighting the progress made during the year-to-date, as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of our website.
On Slide 2, before we start, I would like to remind you that we'll be making forward-looking statements regarding the financial outlook in addition to regulatory and product plan developments. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted.
Slide 3, on today's call, we are very pleased to be joined by Jonathan Dickinson, our new Chief Executive Officer. Jonathan is a seasoned healthcare professional and joins from Incyte. He has a strong background in oncology and previous roles include ARIAD, BMS, Roche and Novartis.
On the next slide, today’s agenda, after an instruction from Jonathan, Sonia Quaratino, our Chief Medical Officer, who will cover updates on the lacutamab and IPH6501 and 4502. We will then hand to Yannis Morel, Chief Operating Officer, who will discuss ANKET platform ADC SITC and monalizumab updates; Arvind Sood, EVP, US Operations will wrap up and close and we’ll also have Frederic Lombard, our CFO on the line for questions.
Jonathan, I now hand the call over to you.
Jonathan Dickinson
Thank you, Henry. Good morning, and good afternoon to everybody on the call. I am very excited to join in a pharma, a company, which is at the forefront of cutting-edge science in oncology. The unit of innovative work being done at Innate is truly inspiring world-class and I'm looking forward to using my extensive oncology experience to shape the Innate portfolio to maximize the future commercial potential, and drive the next chapter of the Innate's exciting journey. I look forward to meeting with as many of you as possible in the coming weeks.